Tvardi Therapeutics, Inc. TVRD
Tvardi Therapeutics, Inc. (Nasdaq: TVRD) is a GI/hepatology drug developer. Its lead program, TTI-109, is in Phase 1 for Ulcerative colitis. Its next catalyst on record is TTI-101 (HCC): Topline data from REVERT LIVER CANCER Phase 1b/2 clinical trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TTI-101 (HCC) — Topline data from REVERT LIVER CANCER Phase 1b/2 clinical trial (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TTI-101 | Hepatocellular carcinoma (HCC) | small molecule | Phase 2 |
| TTI-101 | Idiopathic pulmonary fibrosis (IPF) | small molecule | Phase 2 |
| TTI-109 | Ulcerative colitis | small molecule | Phase 1 |
Recent results and decisions
- Aug 14, 2026positive Tvardi reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming prodrug design, improved tolerability and reductions in disease-relevant immune cell populations.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and, across the active dose range, reductions in cellular and humoral immune populations known to correlate with UC disease severity.
Filing - Jul 30, 2026positive Phase 1 healthy volunteer study of TTI-109 showed placebo-adjusted immune cell reductions, up to 76% in Th17 subsets, 43% in Tfh subsets and 71% in B cell subsets; UC chosen as initial indication.
Broad suppression of pathogenic Th17-associated immune populations, including up to 76% reduction in subsets associated with mucosal destruction and treatment-refractory UC
Filing - Mar 31, 2026mixed Additional REVERT IPF analyses (trial previously missed its goals) showed a 9.4% baseline-weighted reduction in fibrosis score vs 2.4% for placebo and a 4.5-fold greater IL-6 decline.
TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, as well as a 4.5-fold greater decline in IL-6, a central STAT3-driven inflammatory cytokine.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.